

Integrated Filing (Finance) Ind AS

Eyantra Ventures Limited

General Information

Scrip code*	512099
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE750G01019
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	10-02-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	29-01-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Third quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	Operating Segment
Start date of board meeting	10-02-2026
Start time of board meeting	17:30:00
End date of board meeting	10-02-2026
End time of board meeting	18:06:00

Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	

Financial Results - Ind-AS

Amount in (Lakhs)

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-12-2025	31-12-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	2,642.42	6,893.69
	Other income	3.92	23.94
	Total income	2,646.34	6,917.63
2	Expenses		
	(a) Cost of materials consumed	31.49	161.94
	(b) Purchases of stock-in-trade	1,538.16	4,023.59
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	77.89	(122.26)
	(d) Employee benefit expense	599.02	1,714.03
	(e) Finance costs	34.62	93.01
	(f) Depreciation, depletion and amortisation expense	101.01	300.85
	(g) Other Expenses		
	1 Purchase of services	72.95	184.15
	2 other expenses	556.07	1,700.05
	Total other expenses	629.02	1,884.20
	Total expenses	3,011.21	8,055.36
3	Total profit before exceptional items and tax	(364.87)	(1,137.73)

4	Exceptional items	0.00	0.00
5	Total profit before tax	(364.87)	(1,137.73)
6	Tax expense		
7	Current tax	8.12	13.79
8	Deferred tax	(5.12)	1.50
9	Total tax expenses	3.00	15.29
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	Net Profit Loss for the period from continuing operations	(367.87)	(1,153.02)
12	Profit (loss) from discontinued operations before tax	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00
14	Net profit (loss) from discontinued operation after tax	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	Total profit (loss) for period	(367.87)	(1,153.02)
17	Other comprehensive income net of taxes	15.06	14.32
18	Total Comprehensive Income for the period	(352.81)	(1,138.70)
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent	(203.18)	(616.58)
	Total profit or loss, attributable to non-controlling interests	(164.70)	(536.45)
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	(187.94)	(601.81)
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	(166.87)	(536.89)
21	Details of equity share capital		
	Paid-up equity share capital	200.69	200.69
	Face value of equity share capital	10.00	10.00
22	Reserves excluding revaluation reserve		
23	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	(10.12)	(30.72)
	Diluted earnings (loss) per share from continuing operations	(10.12)	(30.72)
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00

	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	(10.12)	(30.72)
	Diluted earnings (loss) per share from continuing and discontinued operations	(10.12)	(30.72)
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)

1. The above statement of Unaudited Consolidated Financial Results for the quarter and nine months ended 31 December, 2025 as reviewed and recommended by the Audit Committee, have been approved and taken on record at the meeting of the Board of Directors held on 10 February, 2026. ' 2. The Unaudited Consolidated Financial Results of the Company have been prepared in accordance with Indian Accounting Standard (IndAS) prescribed under Section 133 of the Companies Act, 2013 (the "Act") read with the Companies (Indian Accounting Standard) Rules, 2015, as amended in terms of Regulation 33 of the SEBI (LODR) Regulations ("Listing Requirements") as amended. ' 3. The Company entered into a share subscription agreement with NEURO AND SPINE ASSOCIATES PRIVATE LIMITED (Investee Company) on 04 October 2024 to subscribe to 75,000 equity (60% of shareholding) shares of Rs. 10 each aggregating to INR 1,500 Lakhs of Investment. The Company has invested INR 1080 Lakhs by subscribing to 54,000 equity shares of Rs. 10 each at Rs. 2,000 per equity share till 30 June 2025 with a shareholding of 51.92% The Company acquired control in terms of INDAS 110, Consolidated Financial Statements in the Investee Company w.e.f 01 April 2025 and accordingly consolidated the investee Company in accordance with INDAS 110 w.e.f 01 April 2025. ' ' 4. Segment reporting ' Particulars Quarter ended Nine Months ended Year ended ' 31-12-2025 30-09-2025 31-12-2024 31-12-2025 31-12-2024 31-03-2025 ' Unaudited Unaudited Unaudited Unaudited Unaudited Audited ' a. Revenue from Customers ' Sale of merchandise 1,906.64 1,360.24 927.65 4,392.19 1,876.96 1,899.56 ' Supply of IT services 301.80 511.66 203.62 1,208.55 612.98 1,370.73 ' Supply of other services - - - - - ' Income from hospital services 343.84 338.1 - 1,013.29 - - ' Sale of pharmacy products 90.14 84.86 - 279.66 - - ' Total 2,642.42 2,294.86 1,131.27 6,893.69 2,489.94 3,270.29 ' b. Geographical Segment Information ' Within India 2,403.80 2,089.07 932.65 6,274.58 1,881.96 2,367.25 ' Outside India 238.62 205.79 198.62 619.11 607.98 903.04 ' Total 2,642.42 2,294.86 1,131.27 6,893.69 2,489.94 3,270.29 ' ' i) Segment information is presented for the "consolidated financial results" as permitted under the Ind AS 108 - 'Operating Segments'. ' ' ii) The Company's operating

business are organised and managed according to nature of Products and services provided. This assessment resulted in identification of (a) Revenue from sale of Merchandise (b) Revenue from software services (c) Revenue from Hospital Services (d) Revenue from Pharmacy product (e) Revenue from other Services as separate lines of business activities at Revenue level, by the Chief Operating Decision Maker (CODM). However, since the Company does not allocate common operating costs, assets and liabilities across business activities, as per the assessment undertaken by CODM, the allocation resources and assessment of the financial performance is undertaken at the Group level. ' ' 6. The Figures of the Previous Years/period have been regrouped/re-arranged wherever considered necessary.

Other Comprehensive Income

Amount in (Lakhs)

Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-10-2025	01-04-2025
Date of end of reporting period	31-12-2025	31-12-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Consolidated	Consolidated
Other comprehensive income [Abstract]		
1 Amount of items that will not be reclassified to profit and loss		
1 (i) Items that will not be reclassified to Profit or Loss	0.56	0.00
2 (ii) Income tax effect on remeasurement of defined benefit liability	13.61	13.61
3 (i) Items that will be reclassified to Statement of Profit and loss	0.89	0.71
Total Amount of items that will not be reclassified to profit and loss	15.06	14.32
2 Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00
3 Amount of items that will be reclassified to profit and loss		
Total Amount of items that will be reclassified to profit and loss		
4 Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5 Total Other comprehensive income	15.06	14.32